Neurology

A study by the American Academy of Neurology suggests that taking a low-dose aspirin once per day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or possible Alzheimer disease.

Ozanimod demonstrated acceptable safety and tolerability in the phase 3 SUNBEAM and RADIANCE part B trials.

The study focused on whether moderate alcohol intake is related to reductions in amyloid-beta deposition or is protective via amyloid-independent mechanisms in the living human brain since little information was available.

The spray is the first nasal spray treatment for seizure cluster rescue.

Few drugs are available to address cognitive decline, but dietary changes, mental and physical activity, and social engagement can all help.

Few drugs are available to address cognitive decline, but dietary changes, mental and physical activity, and social engagement can all help.

Higher dietary intake of flavonols may be associated with a lower risk of developing Alzheimer dementia.

Many options are available, but no single one is effective for all symptoms of this disorder.

The medication works by blocking CGRP receptors, treating a root cause of migraine.

Why is KM taking such a high dose of prednisone?

Study findings provide further basis for dietary interventions as future treatments for disorders such as multiple sclerosis.

The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.

The diazepam nasal spray was granted 7 years of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development.

Patients with epilepsy treated with perampanel during routine clinical care had favorable retention rates and sustained efficacy.

An analysis of efficacy and safety outcomes in patients receiving perampanel as first adjunctive antiepileptic drug found that almost half of the patients were seizure-free.

In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.

Fingolimod treats relapsing forms of multiple sclerosis in adult patients.

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Top news of the day from across the health care landscape.

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.

Top news of the day from across the health care landscape.